ArticleBMC ophthalmology2024
Effect of defocus incorporated multiple segments (DIMS) spectacle lenses on myopia progression in children: a retrospective analysis in a German real-life clinical setting.
Article in BMC ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Evaluating the effect of a new myopia control spectacle lens among children in Israel: 24-month results.Eye (London, England) · 2026Trial
- New design peripheral defocus spectacle lens vs. single-vision for slowing myopia progression in children: randomized controlled trial.Scientific reports · 2025Trial
- Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine for myopia control: a randomised trial in children from Central Europe.BMJ open ophthalmology · 2025Trial
- Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in UK children: Outcomes from a 2-year multi-site interventional trial.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Trial
- Defocus-Incorporated Multiple-Segment (DIMS) Spectacle Lenses Versus Single-Vision Lenses for Myopia Control in a South-Eastern European Population.Bioengineering (Basel, Switzerland) · 2026Article
- Emerging Technologies for the Management and Mitigation of Myopia Progression: A Scoping Review.Health science reports · 2026Article
- Comparative Effectiveness of Three Myopia Control Lenses: A Multicenter, Real-World Study of 5182 Adolescents and Children in Chongqing, China.Translational vision science & technology · 2026Article
- Comparative Effectiveness of Myopia-control Spectacle Lenses: Clincial setting Performance from a Retrospective Cohort Study.Ophthalmology science · 2026Article
- Real-World Comparison of the Effectiveness of Defocus Incorporated Multiple Segments and Myopi-X Spectacle Lenses for Myopia Control in Turkish Children: A Retrospective Study.Turkish journal of ophthalmology · 2026Observational
- Comparative effects of orthokeratology and defocus incorporated multiple segment lenses on axial length elongation in children with bilateral myopic anisometropia.International journal of ophthalmology · 2026Article
- Real-World Effectiveness of DIMS Spectacle Lenses for Myopia Control in a Turkish Pediatric Population: A Retrospective Study Using Age-Specific Physiological Growth Curves.Children (Basel, Switzerland) · 2025Article
- The Role of Spectacle Lenses in the Control and Management of Myopia Progression: A Narrative Review.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis retrospective analysis evaluates the treatment success of "Defocus Incorporated Multiple Segments" (DIMS) spectacle lenses in a real-life clinical setting in Germany. MATERIALS AND
methodsAxial length (AL) and objective refraction of 166 eyes treated with DIMS at baseline and 12-month follow-up were analyzed. Annual AL growth rate within the range of physiological growth rate was considered a successful treatment. Myopia progression of ≥ -0.5 D/yr accounted as treatment success. Differences in percentages of treatment success of subgroups depending on baseline AL and age against treatment success of the total population were investigated.
resultsConsidering all eyes, treatment success regarding AL growth and myopia progression was achieved in 46% and 65%, respectively. Male eyes with moderate AL showed treatment success in a higher proportion (73%, p < 0.01; 89%, p < 0.01); eyes with high AL showed treatment success in a lower proportion (25%, p < 0.01; 51%, n.s.). Female eyes showed the same trend but without statistical significance (moderate AL: 49%; 68%; high AL: 40%; 62%). Younger children showed treatment success in a lower proportion (male: 11%, p < 0.01; 38%, p < 0.05; female: 25%, p < 0.01; 42%, p < 0.01). Older children showed treatment success in a higher proportion (male: 60%, p < 0.05; 78% p < 0.05; female: 53%, n.s.; 77% p < 0.05).
conclusionsEyes with moderate baseline AL and of older children showed treatment success after 12 months of DIMS treatment. Eyes with a high baseline AL and of younger children showed treatment success in a smaller proportion, therefore combination treatment should be considered. In future studies, males and females should be assessed separately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.